RamblinRose

Ascent Enters $200M Pact With Novartis

well, there is more to pepducins than marketing; they do have the potential to work optionally as agonists or antagonists against any GPCR--there are possible specficity issues in some cases, and they are peptides, so parenteral delivery is the only viable delivery method. They also have to get across the cell membrane to work--hence the hydrophobic tether. I think the limitation is that they will be limited to acute delivery situations--some possible first line applications in oncolog, immunosuppression and thrombosis